tradingkey.logo
tradingkey.logo
Search

Dynavax Technologies Corp

DVAX
Add to Watchlist
15.500USD
0.0000.00%
Close 07/01, 16:00ETQuotes delayed by 15 min
1.76BMarket Cap
LossP/E TTM

TradingKey Stock Score of Dynavax Technologies Corp

Currency: USD Updated: 2026-02-09

Key Insights

Dynavax Technologies Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dynavax Technologies Corp's Score

Industry at a Glance

Industry Ranking
41 / 391
Overall Ranking
151 / 4517
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Dynavax Technologies Corp Highlights

StrengthsRisks
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -42.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 115.66M shares, decreasing 9.06% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.65K shares of this stock.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
16.000
Target Price
+3.23%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Dynavax Technologies Corp?

The TradingKey Stock Score provides a comprehensive assessment of Dynavax Technologies Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Dynavax Technologies Corp’s performance and outlook.

How do we generate the financial health score of Dynavax Technologies Corp?

To generate the financial health score of Dynavax Technologies Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Dynavax Technologies Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Dynavax Technologies Corp.

How do we generate the company valuation score of Dynavax Technologies Corp?

To generate the company valuation score of Dynavax Technologies Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Dynavax Technologies Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Dynavax Technologies Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Dynavax Technologies Corp.

How do we generate the earnings forecast score of Dynavax Technologies Corp?

To calculate the earnings forecast score of Dynavax Technologies Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Dynavax Technologies Corp’s future.

How do we generate the price momentum score of Dynavax Technologies Corp?

When generating the price momentum score for Dynavax Technologies Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Dynavax Technologies Corp’s prices. A higher score indicates a more stable short-term price trend for Dynavax Technologies Corp.

How do we generate the institutional confidence score of Dynavax Technologies Corp?

To generate the institutional confidence score of Dynavax Technologies Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Dynavax Technologies Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Dynavax Technologies Corp.

How do we generate the risk management score of Dynavax Technologies Corp?

To assess the risk management score of Dynavax Technologies Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Dynavax Technologies Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Dynavax Technologies Corp.